While biopharmaceutical companies may be thought of as mission oriented, they are almost certainly the poster children for adaptation. They need to focus on finding the most pressing relevant issues to help their patients.

When asked how to boost America’s educational competiveness, a staple response is the emphatic assertion that we need to be more like nation X.  But, just for a moment, let’s entertain the radical proposition that a better course is to tap into uniquely American strengths like federalism, entrepreneurial dynamism, and size and heterogeneity.

Bankers have created an amazing bubble, an international panic and a massively costly bust.

Rapid growth in the P2P industry has given rise to concerns over appropriate regulation of this alternative form of lending.

Every serious study of U.S. infrastructure has reached the same conclusion: More investment is needed -- and fast. But with Sen. Jeff Bingaman's amendment to the highway reauthorization bill, the Senate effectively penalizes states for using innovative infrastructure financing.

There are good reasons for the European Union to worry about the health of its pharmaceutical firms, but fortunately there are things it can improve.

How severe is the crisis in the pharmaceutical industry?

Indicator-based competitionshiftsthe locus of development from aid agencies to local governments in developing countries.